Volume 69, Issue 12, Pages (June 2006)

Slides:



Advertisements
Similar presentations
An alcoholic patient with recurrent renal failure and proteinuria T. Kumagai, Y. Hori, G. Seki, Toshiro Fujita Kidney International Volume 70, Issue 8,
Advertisements

V.M. Campese, N. Mitra, D. Sandee  Kidney International 
Beta blockers in the management of chronic kidney disease
Volume 70, Issue 10, Pages (November 2006)
Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction 
Viper venom for diabetic nephropathy
Thinking Beyond New Clinical Guidelines: Update in Hypertension
Biomarker explorations in acute kidney injury: the journey continues
Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani 
Membranous nephropathy: When and how to treat
Viper venom for diabetic nephropathy
John P. Middleton, Patrick H. Pun  Kidney International 
Renoprotective effects of vitamin D analogs
Audit-based education: a potentially effective program for improving guideline achievement in CKD patients  Moniek C.M. de Goeij, Joris I. Rotmans  Kidney.
Proteinuria in diabetic kidney disease: A mechanistic viewpoint
V.M. Campese, N. Mitra, D. Sandee  Kidney International 
Volume 84, Issue 1, Pages (July 2013)
Steven J. Rosansky, Richard J. Glassock  Kidney International 
Volume 70, Issue 11, Pages (December 2006)
Volume 72, Issue 12, Pages (December 2007)
Filtration function in glomerulonephritis
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Volume 71, Issue 11, Pages (June 2007)
Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension  A. Davenport, C. Cox, R. Thuraisingham  Kidney.
Volume 71, Issue 11, Pages (June 2007)
Cell cycle regulatory proteins in glomerular disease
Volume 71, Issue 6, Pages (March 2007)
Saulo Klahr, Jeremiah J. Morrissey  Kidney International 
Volume 70, Issue 12, Pages (December 2006)
Volume 70, Issue 7, Pages (October 2006)
Fructose intake as a risk factor for kidney stone disease
David M. Charytan, John P. Forman  Kidney International 
The management of CKD: A look into the future
Special deLIVERy: podocyte injury promotes renal angiotensin II generation from liver- derived angiotensinogen  David I. Ortiz-Melo, Robert F. Spurney 
The third World Kidney Day: Looking back and thinking forward
Volume 72, Issue 2, Pages (July 2007)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
The future of renoprotection: Frustration and promises
Methods for guideline development
Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes  J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.
Old friends form alliance against podocytes
Yin and Yang: The Dao of the kidney
Michael W. Steffes, Derek Schmidt, Rebecca Mccrery, John M. Basgen 
Volume 71, Issue 4, Pages (February 2007)
Karen A. Griffin, Anil K. Bidani  Kidney International 
Volume 82, Issue 9, Pages (November 2012)
Volume 81, Issue 7, Pages (April 2012)
Volume 73, Issue 5, Pages (March 2008)
Volume 53, Issue 6, Pages (June 1998)
Organ transplantation goes to the movies
Molecular mechanisms of renal hypertrophy: Role of p27Kip1
Volume 72, Issue 2, Pages (July 2007)
Volume 80, Issue 10, Pages (November 2011)
An IRKO in the Podo: Impaired Insulin Signaling in Podocytes and the Pathogenesis of Diabetic Nephropathy  Susan B. Gurley, Thomas M. Coffman  Cell Metabolism 
Volume 81, Issue 12, Pages (June 2012)
Is it the low-protein diet or simply the salt restriction?
Volume 70, Issue 3, Pages (August 2006)
Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular.
Volume 70, Issue 5, Pages (September 2006)
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications 
Volume 70, Issue 10, Pages (November 2006)
The International Pediatric Peritonitis Registry: Starting to walk
Volume 69, Issue 11, Pages (June 2006)
Volume 57, Issue 2, Pages (October 2000)
Volume 72, Issue 8, Pages (October 2007)
Proteinuria and hypertension with tyrosine kinase inhibitors
Renoprotection with vitamin D: Specific for diabetic nephropathy?
Podocyte GTPases regulate kidney filter dynamics
Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis  Eero O. Honkanen, Anna-Maija Teppo, Carola.
Presentation transcript:

Volume 69, Issue 12, Pages 2131-2147 (June 2006) The podocyte's response to injury: Role in proteinuria and glomerulosclerosis  S.J. Shankland  Kidney International  Volume 69, Issue 12, Pages 2131-2147 (June 2006) DOI: 10.1038/sj.ki.5000410 Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 1 Podocyte response to injury. Podocytes are injured by immune- and non-immune-mediated disease, resulting in damage to the glomerular filtration barrier. This typically results in proteinuria and effacement. The fate of the podocyte then depends on several factors, such as reparative mechanisms. If these are present, and/or the initial injury is halted, there may be resolution. However, if injury persists, and/or there are inadequate repair mechanisms presents, proteinuria persists, with the development of glomerulosclerosis, leading to reduced renal function. Kidney International 2006 69, 2131-2147DOI: (10.1038/sj.ki.5000410) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 2 Factors governning podocyte number. Total podocyte (podo) number is a balance between proliferation and loss. Podocyte number is reduced by either a decrease in proliferation owing to lack of DNA synthesis, DNA damage or hypertrophy, and/or an in crease in podocyte loss owing to detachment and apoptosis. Kidney International 2006 69, 2131-2147DOI: (10.1038/sj.ki.5000410) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 3 Injurious effects of angiotensin II on podocytes. The numerous deleterious actions of angiotensin II (AT) and its receptor are shown, providing the rationale for the use of angiotensin-converting enzyme Inhibitors and angiotensin receptor blockers in patients with proteinuria. Kidney International 2006 69, 2131-2147DOI: (10.1038/sj.ki.5000410) Copyright © 2006 International Society of Nephrology Terms and Conditions